Greta A Bushnell1, Til Stürmer1, Sonja A Swanson1, Alice White1, Deborah Azrael1, Virginia Pate1, Matthew Miller1. 1. Ms. Bushnell, Dr. Stürmer, Dr. White, and Ms. Pate are with the Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill (e-mail: gbushnel@live.unc.edu ). Dr. Swanson is with the Department of Epidemiology, Erasmus MC, Rotterdam, the Netherlands, and the Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston. Dr. Azrael is with the Department of Health Policy and Management, Harvard T. H. Chan School of Public Health, Boston. Dr. Miller is with the Department of Health Sciences, Bouvé College of Health Sciences, Northeastern University, Boston.
Abstract
OBJECTIVE: Prior research evaluated various effects of the 2004 black-box warning by the U.S. Food and Drug Administration (FDA) on the risk of suicidality among children associated with use of antidepressants, but the warning's effect on dosing of antidepressants has not been evaluated. This study estimated whether the initial antidepressant dose prescribed decreased and the proportion of patients who augmented the dose on the second fill increased following the 2004 warning and its 2007 expansion to young adults. METHODS: The study utilized the LifeLink Health Plan Claims Database. The study cohort consisted of commercially insured children (ages 5-17), young adults (18-24), and adults (25-64) who initiated a selective serotonin reuptake inhibitor (SSRI) (citalopram, fluoxetine, paroxetine, or sertraline) from January 1, 2000, to December 31, 2009. Dose per day was determined by days' supply, strength, and quantity dispensed. Initiation with a low dose and augmentation of >1 mg/day on the second prescription before and after the 2004 warning were considered. RESULTS: Of 51,948 children who initiated an SSRI, 15% initiated with a low dose before the 2004 warning compared with 31% after the warning; there was a smaller change among young adults (6 percentage points) and adults (3 percentage points). The overall increase in dose augmentations among children and young adults was driven by the increase in patients initiating with a low dose. CONCLUSIONS: The proportion of commercially insured children initiating an SSRI with a low dose was higher after the 2004 FDA warning on the risk of suicidality among children, suggesting improved prescribing practices surrounding SSRI dosing among children.
OBJECTIVE: Prior research evaluated various effects of the 2004 black-box warning by the U.S. Food and Drug Administration (FDA) on the risk of suicidality among children associated with use of antidepressants, but the warning's effect on dosing of antidepressants has not been evaluated. This study estimated whether the initial antidepressant dose prescribed decreased and the proportion of patients who augmented the dose on the second fill increased following the 2004 warning and its 2007 expansion to young adults. METHODS: The study utilized the LifeLink Health Plan Claims Database. The study cohort consisted of commercially insured children (ages 5-17), young adults (18-24), and adults (25-64) who initiated a selective serotonin reuptake inhibitor (SSRI) (citalopram, fluoxetine, paroxetine, or sertraline) from January 1, 2000, to December 31, 2009. Dose per day was determined by days' supply, strength, and quantity dispensed. Initiation with a low dose and augmentation of >1 mg/day on the second prescription before and after the 2004 warning were considered. RESULTS: Of 51,948 children who initiated an SSRI, 15% initiated with a low dose before the 2004 warning compared with 31% after the warning; there was a smaller change among young adults (6 percentage points) and adults (3 percentage points). The overall increase in dose augmentations among children and young adults was driven by the increase in patients initiating with a low dose. CONCLUSIONS: The proportion of commercially insured children initiating an SSRI with a low dose was higher after the 2004 FDA warning on the risk of suicidality among children, suggesting improved prescribing practices surrounding SSRI dosing among children.
Authors: Bill Lyndon; Leanne Rowe; Allen Fraser; Daryl Efron; Garry Walter; Ian Wilson; Louise Newman; Natalie Silove Journal: Aust Fam Physician Date: 2005-09
Authors: Stacie B Dusetzina; Ashley S Higashi; E Ray Dorsey; Rena Conti; Haiden A Huskamp; Shu Zhu; Craig F Garfield; G Caleb Alexander Journal: Med Care Date: 2012-06 Impact factor: 2.983
Authors: Graham Emslie; Christopher Kratochvil; Benedetto Vitiello; Susan Silva; Taryn Mayes; Steven McNulty; Elizabeth Weller; Bruce Waslick; Charles Casat; John Walkup; Sanjeev Pathak; Paul Rohde; Kelly Posner; John March Journal: J Am Acad Child Adolesc Psychiatry Date: 2006-12 Impact factor: 8.829
Authors: Anne M Libby; David A Brent; Elaine H Morrato; Heather D Orton; Richard Allen; Robert J Valuck Journal: Am J Psychiatry Date: 2007-06 Impact factor: 18.112
Authors: Andrew R Zullo; David D Dore; Lori Daiello; Rosa R Baier; Roee Gutman; David R Gifford; Robert J Smith Journal: J Am Med Dir Assoc Date: 2016-03-24 Impact factor: 4.669
Authors: Greta A Bushnell; Til Stürmer; Christina Mack; Virginia Pate; Matthew Miller Journal: Pharmacoepidemiol Drug Saf Date: 2018-10-31 Impact factor: 2.890
Authors: Ymkje Anna de Vries; Peter de Jonge; Luuk Kalverdijk; Jens H J Bos; Catharina C M Schuiling-Veninga; Eelko Hak Journal: Eur Child Adolesc Psychiatry Date: 2016-03-17 Impact factor: 4.785
Authors: Margaret E Gerbasi; Samantha Meltzer-Brody; Sarah Acaster; Moshe Fridman; Vijayveer Bonthapally; Paul Hodgkins; Stephen J Kanes; Adi Eldar-Lissai Journal: J Womens Health (Larchmt) Date: 2020-11-12 Impact factor: 2.681